Get the Stockscreener App
2.5728
3.02%
-0.0772
Sight Sciences Inc stock is traded at $2.5728, with a volume of 79,754.
It is down -3.02% in the last 24 hours and down -5.86% over the past month.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
See More
Previous Close:
$2.65
Open:
$2.68
24h Volume:
79,754
Relative Volume:
0.35
Market Cap:
$132.55M
Revenue:
$81.06M
Net Income/Loss:
$-55.55M
P/E Ratio:
-2.2568
EPS:
-1.14
Net Cash Flow:
$-47.98M
1W Performance:
+4.47%
1M Performance:
-5.86%
6M Performance:
-59.14%
1Y Performance:
-37.47%
1-Day Range:
$2.5601
$2.82
1-Week Range:
$2.29
$2.875
52-Week Range:
$2.29
$8.45
Sight Sciences Inc Stock (SGHT) Company Profile
Name
Sight Sciences Inc
Sector
Industry
Phone
(415) 889-0550
Address
4040 CAMPBELL AVE,, MENLO PARK
Compare SGHT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
2.57 | 132.55M | 81.06M | -55.55M | -47.98M | -1.14 |
|
ABT
Abbott Laboratories
|
140.52 | 241.69B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.37 | 153.75B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
396.98 | 150.24B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
94.67 | 120.56B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.82 | 42.42B | 5.72B | 4.17B | 490.10M | 6.97 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | UBS | Buy |
| Nov-04-24 | Downgrade | Lake Street | Buy → Hold |
| Aug-21-24 | Initiated | Lake Street | Buy |
| Sep-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-12-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-24-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-23 | Upgrade | Stifel | Hold → Buy |
| Oct-04-22 | Initiated | Needham | Hold |
| Jul-26-22 | Initiated | Stifel | Hold |
| Feb-03-22 | Initiated | William Blair | Outperform |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Sight Sciences Inc Stock (SGHT) Latest News
March 2025 Penny Stocks To Consider For Growth - Simply Wall St
Sight Sciences (SGHT) Projected to Post Earnings on Wednesday - Defense World
Sight Sciences (SGHT) to Release Quarterly Earnings on Wednesday - MarketBeat
Will Sight Sciences, Inc. (SGHT) Report Negative Earnings Next Week? What You Should Know - MSN
Institutional owners may consider drastic measures as Sight Sciences, Inc.'s (NASDAQ:SGHT) recent US$14m drop adds to long-term losses - Simply Wall St
Sight Sciences To Present Clinical Data On OMNI Surgical System At AGS Annual Meeting 2025 - Nasdaq
Sight Sciences stock hits 52-week low at $2.47 amid market challenges - Investing.com Nigeria
Sight Sciences to Present Comprehensive Clinical Data on - GlobeNewswire
Can This Groundbreaking Glaucoma Treatment Transform Patient Care? New Data Reveals 3-Year Outcomes - StockTitan
Sight Sciences stock hits 52-week low at $2.47 amid market challenges By Investing.com - Investing.com South Africa
Critical Contrast: Microbot Medical (NASDAQ:MBOT) vs. Sight Sciences (NASDAQ:SGHT) - Defense World
Sight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025 - The Manila Times
Can Sight Sciences Maintain Growth Momentum? Q4 Earnings Date Revealed - StockTitan
Analysts Set Sight Sciences, Inc. (NASDAQ:SGHT) Target Price at $4.68 - MarketBeat
Sight Sciences, Inc. (NASDAQ:SGHT) Receives Consensus Rating of “Hold” from Analysts - Defense World
Stifel maintains Buy rating and $5 target on Sight Sciences stock - Investing.com Australia
Stifel maintains Buy rating and $5 target on Sight Sciences stock By Investing.com - Investing.com South Africa
Sight sciences CTO David Badawi sells $15,081 in stock - MSN
Sight Sciences stock hits 52-week low at $2.54 amid market challenges - MSN
SG Americas Securities LLC Grows Stake in Sight Sciences, Inc. (NASDAQ:SGHT) - Defense World
Sight Sciences to Present at Citi’s 2025 Unplugged MedTech and Life Sciences Access Day - GlobeNewswire
Sight Sciences to Present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day - The Manila Times
Exclusive: Sight Sciences to Unveil Latest Eye Care Innovation Strategy at Major Citi Conference - StockTitan
Sight Sciences stock hits 52-week low at $2.54 amid market challenges By Investing.com - Investing.com South Africa
Raymond James downgrades Third Harmonic Bio on uncertainty for only asset - MSN
Ivanhoe Electric shares fall on public offering of units - MSN
Amarc to acquire 100% interest in adjacent Brenda property - MSN
Stifel Nicolaus Cuts Sight Sciences (NASDAQ:SGHT) Price Target to $5.00 - MarketBeat
Dry Eye Treatment Devices Market Poised to Attain Valuation of US$ 898.78 Million By 2033 | Pharmacological Synergy Driving Demand for Advanced Dry Eye Treatment Devices Says Astute Analytica - GlobeNewswire Inc.
Stifel Nicolaus Issues Pessimistic Forecast for Sight Sciences (NASDAQ:SGHT) Stock Price - Defense World
Life Sciences Group Of The Year: Cooley - Law360
What 6 Analyst Ratings Have To Say About Sight Sciences - Benzinga
Silexion Therapeutics announces exercise of warrants for $3.3M gross proceeds - MSN
Sight Sciences executives receive salary increases and bonus targets By Investing.com - Investing.com Nigeria
Sight Sciences executives receive salary increases and bonus targets - MSN
JPMorgan Chase & Co. Acquires 53,658 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) - Defense World
Sight Sciences Enhances Executive Compensation for 2025 - TipRanks
Sight Sciences price target lowered to $5 from $5.50 at UBS - MSN
Sight Sciences (NASDAQ:SGHT) Price Target Cut to $5.00 by Analysts at UBS Group - Defense World
UBS Group Cuts Sight Sciences (NASDAQ:SGHT) Price Target to $5.00 - MarketBeat
Sight Sciences, Inc. (NASDAQ:SGHT) Receives $4.72 Average PT from Analysts - MarketBeat
The Hain Celestial Group, Inc. (NASDAQ:HAIN) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Sight Sciences, Inc. (NASDAQ:SGHT) Given Average Recommendation of “Hold” by Brokerages - Defense World
Promising US Penny Stocks To Consider In January 2025 - Simply Wall St
Have Sight Sciences Insiders Been Selling Stock? - Simply Wall St
Long Focus Capital Management, LLC Increases Stake in Sight Scie - GuruFocus.com
Sight Sciences, Inc. (NASDAQ:SGHT) CEO Sells $72,471.48 in Stock - MarketBeat
Sight Sciences Inc Stock (SGHT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sight Sciences Inc Stock (SGHT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Badawi Paul | President and CEO |
Jan 16 '25 |
Sale |
2.92 |
24,819 |
72,571 |
5,676,331 |
| HAYDEN JEREMY B. | Chief Legal Officer |
Jan 17 '25 |
Sale |
2.78 |
6,922 |
19,250 |
145,091 |
2.10%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):